MedPath

Eyenovia's Phase 3 CHAPERONE Study Fails to Meet Primary Endpoint for Pediatric Myopia

• Eyenovia's CHAPERONE Phase 3 trial, evaluating low-dose atropine via Optejet for pediatric myopia, did not meet its primary endpoint of slowing myopia progression over three years. • An independent Data Review Committee found no significant difference in myopia progression between the active treatment arms (0.01% and 0.1% atropine) and placebo. • Eyenovia plans to discontinue the CHAPERONE study, conduct a thorough data review, and assess strategic options, including potential business combinations or asset sales. • The company reports that all dosages and placebo were well-tolerated, with a mild adverse event profile observed during the study.

Eyenovia Inc. (NASDAQ: EYEN) announced that its Phase 3 CHAPERONE study failed to meet its primary efficacy endpoint. The study was designed to evaluate the effectiveness of low-dose atropine delivered via Eyenovia's Optejet dispensing platform as a treatment for pediatric progressive myopia.
The CHAPERONE trial aimed to demonstrate a less than 0.5 diopter progression in visual acuity over three years in children with progressive myopia. However, an independent Data Review Committee (DRC) found that the trial did not meet this primary endpoint after reviewing data from 252 evaluable patients.

Study Findings

The DRC's analysis revealed that there was no statistically significant difference in the rate of myopia progression between the two active treatment arms, which included 0.01% and 0.1% atropine ophthalmic metered spray, and the placebo group. The safety analysis indicated that all dosages and the placebo were well-tolerated, with only mild and infrequent adverse events reported.
"We are disappointed that the DRC determined that the CHAPERONE study does not appear to be meeting its primary efficacy endpoint," stated Michael Rowe, Chief Executive Officer of Eyenovia. "We plan to terminate the study, review the data more thoroughly, and evaluate next steps."

Next Steps for Eyenovia

In light of these results, Eyenovia is considering various strategic options to maximize value for its stakeholders. These options may include a business combination, reverse merger, asset sales, or a combination of these alternatives. The company plans to provide further updates after completing its evaluation.

About Eyenovia and Optejet

Eyenovia, Inc. is an ophthalmic technology company focused on developing and commercializing products that utilize its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is designed for ease of use, enhanced safety and tolerability, and improved compliance, targeting chronic front-of-the-eye diseases. Eyenovia's current commercial portfolio includes clobetasol propionate ophthalmic suspension, 0.05%, for post-surgical pain and inflammation, and Mydcombi® for mydriasis. The company also has licensing and development agreements for additional indications, including dry eye.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Neumora's Navacaprant Fails Phase 3 Trial for Major Depressive Disorder

Neumora Therapeutics' navacaprant failed to meet the primary endpoint in its Phase 3 KOASTAL-1 study for major depressive disorder (MDD).
The trial did not demonstrate a statistically significant improvement in depressive symptoms compared to placebo, as measured by the MADRS scale.

Percheron Therapeutics Discontinues Avicursen Trial for Duchenne Muscular Dystrophy After Phase 2 Failure

Percheron Therapeutics halted its Phase 2b trial of avicursen in non-ambulatory Duchenne muscular dystrophy patients due to the drug failing to meet its primary endpoint.
The trial, conducted in Australia and Europe, showed no significant efficacy benefits after six months of treatment, despite avicursen demonstrating a favorable safety profile.

SKYSCRAPER-01 Phase 3 Trial: Tisotumab Vedotin Fails to Improve Outcomes in Advanced Lung Cancer

The Phase 3 SKYSCRAPER-01 trial evaluating tisotumab vedotin plus pembrolizumab and platinum chemotherapy did not meet its primary endpoint of overall survival in advanced non-small cell lung cancer.
No statistically significant improvement was observed in progression-free survival or objective response rate with the addition of tisotumab vedotin to the chemotherapy and pembrolizumab regimen.

SKYSCRAPER-01: Tiragolumab Plus Atezolizumab Fails to Improve Overall Survival in PD-L1-High NSCLC

Roche's SKYSCRAPER-01 phase 3 trial evaluating tiragolumab plus atezolizumab did not meet its primary endpoint of overall survival in PD-L1-high NSCLC patients.
The combination therapy's safety profile remained consistent with previous reports, and no new safety signals were identified during the study.

Cassava Sciences' Simufilam Fails Phase 3 Alzheimer's Trial, Halting Further Development

Cassava Sciences' Phase 3 ReThink-ALZ trial of simufilam in mild-to-moderate Alzheimer's disease did not meet its co-primary endpoints, indicating no significant cognitive or functional benefit.
Due to the disappointing results, Cassava Sciences is discontinuing its second Phase 3 trial, ReFocus-ALZ, and the Open Label Extension study, effectively halting simufilam's development.

Eyenovia's Stock Plummets After Phase III Myopia Trial Fails to Meet Primary Endpoint

Eyenovia's stock price plummeted after its Phase III CHAPERONE study, evaluating a drug-device combination for pediatric progressive myopia, failed to meet its primary endpoint.
The CHAPERONE trial assessed low-dose atropine delivered via the Optejet platform but did not demonstrate a statistically significant difference in myopia progression compared to the comparator arm.

Eyenovia's Myopia Trial Fails, Stock Plummets

Eyenovia's stock price plummeted after its Phase III CHAPERONE study for pediatric progressive myopia failed to meet the primary endpoint.
The CHAPERONE trial assessed a low-dose atropine formulation delivered via the Optejet platform but did not demonstrate a significant difference in myopia progression compared to the comparator.

Eyenovia's Phase 3 CHAPERONE Study Fails to Meet Primary Endpoint in Pediatric Myopia

Eyenovia's Phase 3 CHAPERONE study, evaluating low-dose atropine via Optejet for pediatric myopia, did not meet its primary endpoint of less than 0.5 diopter progression over three years.
An independent Data Review Committee found no significant difference in myopia progression between the atropine treatment arms (0.01% and 0.1%) and the placebo group.

Eyenovia Halts Phase III Myopia Trial, Explores Strategic Alternatives

Eyenovia discontinues its Phase III clinical trial for a drug-device combination product aimed at treating pediatric myopia after an unfavorable assessment by the data monitoring committee.
The committee determined that the trial was unlikely to meet its primary endpoint, leading Eyenovia to cease the study and re-evaluate its strategic direction.

Eyenovia's Phase 3 CHAPERONE Study Fails to Meet Primary Endpoint in Pediatric Myopia

Eyenovia's Phase 3 CHAPERONE study, evaluating low-dose atropine for pediatric progressive myopia, did not meet its primary endpoint.
The Data Review Committee found no significant difference in myopia progression between atropine (0.01% and 0.1%) and placebo groups.

Reference News

[1]
Eyenovia Provides Update on Phase 3 CHAPERONE Study - GlobeNewswire
globenewswire.com · Nov 15, 2024

Eyenovia's CHAPERONE Phase 3 study fails to meet primary endpoint of less than 0.5 diopter progression in visual acuity ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy